{"id":391503,"date":"2014-11-13T00:00:00","date_gmt":"2014-11-13T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforeu0614-biopharma-oncology-securing-favorable-reimbursement-status-in-the-eu5-oncology-markets-evolving-physician\/"},"modified":"2026-03-31T09:04:24","modified_gmt":"2026-03-31T09:04:24","slug":"pforeu0614-biopharma-oncology-securing-favorable-reimbursement-status-in-the-eu5-oncology-markets-evolving-physician","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforeu0614-biopharma-oncology-securing-favorable-reimbursement-status-in-the-eu5-oncology-markets-evolving-physician\/","title":{"rendered":"Oncology (Securing Favorable Reimbursement Status in the EU5 Oncology Markets: Evolving Physician and Payer Perspectives on Biomarker-Driven Prescribing in Oncology) | Physician &#038; Payer Forum | EU5 | 2014"},"content":{"rendered":"<p>As oncology increasingly moves toward personalized approaches to therapy, the use of predictive biomarkers will become more important. A plethora of biomarker-driven brands are already available for several oncology indications, including breast cancer, colorectal cancer, and non-small-cell lung cancer, and many more such therapies are in the pipeline. Biomarkers enable the selection of patient populations likely to respond to a particular therapy and thus limit treatment costs by preventing a therapy\u2019s uptake among patients unlikely to respond to treatment. As a result, hospital and clinician funds can be allocated more efficiently. The drug labels that restrict treatment to biomarker-positive patients also allow tighter control of spending, especially in the cost-conscious EU5 countries.<\/p>\n","protected":false},"template":"","class_list":["post-391503","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-colorectal-cancer","biopharma-therapy-areas-oncology","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391503","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391503\/revisions"}],"predecessor-version":[{"id":576991,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391503\/revisions\/576991"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391503"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}